Cargando…
Description and Analysis of Cytokine Storm in Registered COVID-19 Clinical Trials: A Systematic Review
The purpose of this systematic review was to describe the characteristics of clinical trials that focused on COVID-19 patients with cytokine release syndrome (CRS) and the variability in CRS definitions. Two authors independently searched three clinical trial registries and included interventional c...
Autores principales: | , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8229812/ https://www.ncbi.nlm.nih.gov/pubmed/34199506 http://dx.doi.org/10.3390/pathogens10060692 |
_version_ | 1783713066705223680 |
---|---|
author | Eljaaly, Khalid Malibary, Husam Alsulami, Shaimaa Albanji, Muradi Badawi, Mazen Al-Tawfiq, Jaffar A. |
author_facet | Eljaaly, Khalid Malibary, Husam Alsulami, Shaimaa Albanji, Muradi Badawi, Mazen Al-Tawfiq, Jaffar A. |
author_sort | Eljaaly, Khalid |
collection | PubMed |
description | The purpose of this systematic review was to describe the characteristics of clinical trials that focused on COVID-19 patients with cytokine release syndrome (CRS) and the variability in CRS definitions. Two authors independently searched three clinical trial registries and included interventional clinical trials on COVID-19 hospitalized patients that required at least one elevated inflammatory biomarker. Relevant data, including the type and cutoff of the measured biomarker, oxygen/respiratory criteria, fever, radiologic criteria, and medications, were summarized. A total of 47 clinical trials were included. The included studies considered the following criteria: oxygen/respiratory criteria in 42 trials (89%), radiologic criteria in 29 trials (62%), and fever in 6 trials (18%). Serum ferritin was measured in 35 trials (74%), CRP in 34 trials (72%), D-dimer in 26 trials (55%), LDH in 24 trials (51%), lymphocyte count in 14 trials (30%), and IL-6 in 8 trials (17%). The cutoff values were variable for the included biomarkers. The most commonly used medications were tocilizumab, in 15 trials (32%), and anakinra in 10 trials (24.4%). This systematic review found high variability in CRS definitions and associated biomarker cutoff values in COVID-19 clinical trials. We call for a standardized definition of CRS, especially in COVID-19 patients. |
format | Online Article Text |
id | pubmed-8229812 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2021 |
publisher | MDPI |
record_format | MEDLINE/PubMed |
spelling | pubmed-82298122021-06-26 Description and Analysis of Cytokine Storm in Registered COVID-19 Clinical Trials: A Systematic Review Eljaaly, Khalid Malibary, Husam Alsulami, Shaimaa Albanji, Muradi Badawi, Mazen Al-Tawfiq, Jaffar A. Pathogens Systematic Review The purpose of this systematic review was to describe the characteristics of clinical trials that focused on COVID-19 patients with cytokine release syndrome (CRS) and the variability in CRS definitions. Two authors independently searched three clinical trial registries and included interventional clinical trials on COVID-19 hospitalized patients that required at least one elevated inflammatory biomarker. Relevant data, including the type and cutoff of the measured biomarker, oxygen/respiratory criteria, fever, radiologic criteria, and medications, were summarized. A total of 47 clinical trials were included. The included studies considered the following criteria: oxygen/respiratory criteria in 42 trials (89%), radiologic criteria in 29 trials (62%), and fever in 6 trials (18%). Serum ferritin was measured in 35 trials (74%), CRP in 34 trials (72%), D-dimer in 26 trials (55%), LDH in 24 trials (51%), lymphocyte count in 14 trials (30%), and IL-6 in 8 trials (17%). The cutoff values were variable for the included biomarkers. The most commonly used medications were tocilizumab, in 15 trials (32%), and anakinra in 10 trials (24.4%). This systematic review found high variability in CRS definitions and associated biomarker cutoff values in COVID-19 clinical trials. We call for a standardized definition of CRS, especially in COVID-19 patients. MDPI 2021-06-02 /pmc/articles/PMC8229812/ /pubmed/34199506 http://dx.doi.org/10.3390/pathogens10060692 Text en © 2021 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/). |
spellingShingle | Systematic Review Eljaaly, Khalid Malibary, Husam Alsulami, Shaimaa Albanji, Muradi Badawi, Mazen Al-Tawfiq, Jaffar A. Description and Analysis of Cytokine Storm in Registered COVID-19 Clinical Trials: A Systematic Review |
title | Description and Analysis of Cytokine Storm in Registered COVID-19 Clinical Trials: A Systematic Review |
title_full | Description and Analysis of Cytokine Storm in Registered COVID-19 Clinical Trials: A Systematic Review |
title_fullStr | Description and Analysis of Cytokine Storm in Registered COVID-19 Clinical Trials: A Systematic Review |
title_full_unstemmed | Description and Analysis of Cytokine Storm in Registered COVID-19 Clinical Trials: A Systematic Review |
title_short | Description and Analysis of Cytokine Storm in Registered COVID-19 Clinical Trials: A Systematic Review |
title_sort | description and analysis of cytokine storm in registered covid-19 clinical trials: a systematic review |
topic | Systematic Review |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8229812/ https://www.ncbi.nlm.nih.gov/pubmed/34199506 http://dx.doi.org/10.3390/pathogens10060692 |
work_keys_str_mv | AT eljaalykhalid descriptionandanalysisofcytokinestorminregisteredcovid19clinicaltrialsasystematicreview AT malibaryhusam descriptionandanalysisofcytokinestorminregisteredcovid19clinicaltrialsasystematicreview AT alsulamishaimaa descriptionandanalysisofcytokinestorminregisteredcovid19clinicaltrialsasystematicreview AT albanjimuradi descriptionandanalysisofcytokinestorminregisteredcovid19clinicaltrialsasystematicreview AT badawimazen descriptionandanalysisofcytokinestorminregisteredcovid19clinicaltrialsasystematicreview AT altawfiqjaffara descriptionandanalysisofcytokinestorminregisteredcovid19clinicaltrialsasystematicreview |